New business opens in Boston suburb

March 3, 2012 by  

The Andover business community welcomes Navidea Biopharmaceuticals Inc. to the New England Business Centre, a Class A business park off Route 93. The launch of a new business is always an excellent opportunity for print companies to develop new relationships and increase their customer base.

Navidea deals in specialty pharmaceuticals and self-describes itself as a company that focuses on precision diagnostic radiopharmaceuticals.

“We are pleased to announce this expansion into the Boston area, a major hub of the biopharmaceutical industry, which will enhance our access to industry partners, key business and technical leaders, and major academic medical centers,” said president and chief operating officer of Navidea, Dr. Mark Pickett.

This newly opened location is where Navidea’s commercialization personnel is actively developing a new product and preparing a marketing plan to launch the cancer diagnostic pharmaceutical called Lymphoseek, scheduled to hit the market late in 2012. Lyphoseek is touted as the first receptor targeted agent for lymphatic mapping in cancer treatments. At present, the launch is pending review results from the FDA for Lymphoseek. Navidea anticipates a response during the summer. Approved for marketing in Europe, Lymphoseek is yet to pass review by the FDA. In a recent media release, Navidea said those results are expected mid-year.

Navidea Biopharmaceuticals Inc. is a publicly traded company with its head office in Dublin, Ohio where many of their administration and manufacturing functions remain. They have 40 employees worldwide with a focus on diagnostic pharmaceuticals for cancer and Alzheimer’s disease.